Pulmonary-Allergy Drugs

At July 23 meeting, the FDA Advisory Committee will discuss two lung surfactant extracts: Burroughs Wellcome's synthetic extract Exosurf (colfosceril palmitate) and Survanta (beractant), a bovine lung surfactant TA from Abbott's Ross Labs subsidiary. Both products are currently available under Treatment INDs for respiratory distress syndrome in premature infants (also called hyaline membrane disease), an orphan indication. Exosurf received a Treatment IND in July 1989; Survanta in October 1989.